Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab [8]

Leukemia

Volumn 19, Issue 11, 2005, Pages 2005-2008

  Schutzinger C ^a   Gaiger, A ^a   Thalhammer, R ^a   Vesely, M ^a   Fritsche Polanz, R ^a   Schwarzinger, I ^a   Ohler L ^a   Simonitsch Klupp, I ^a   Reinhard, F ^a   Jäger, Ulrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ERYTHROPOIETIN; FLUDARABINE; HEMOGLOBIN; METHOTREXATE; PREDNISONE; T LYMPHOCYTE RECEPTOR;

AGED; BLOOD TRANSFUSION; CANCER STAGING; CASE REPORT; CHILL; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEVER; HEMOGLOBIN DETERMINATION; HERPES ZOSTER; HUMAN; LARGE GRANULAR LYMPHOCYTE; LETTER; LOW DRUG DOSE; LYMPHATIC LEUKEMIA; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REMISSION; RETICULOCYTE COUNT; T CELL LEUKEMIA;

EID: 27644488002     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403956     Document Type: Letter

References (8)

1. Chan WC, Catovsky D, Foucar K, Montserrat E. T-celll large lymphocyte leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). The WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001, pp 197-198.
2. Burks EJ. Loughran Jr TP. Perspectives in the treatment of LGL leukemia. Leuk Res 2005; 29: 123-125.
3. Kwong YL, Wong KF. Association of pure red cell aplasia with T large granular lymphocyte leukaemia. J Clin Pathol 1998; 51: 672-675.
4. Xiuqing R, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003; 123: 278-281.
5. Osuji N, Matutes E, Wotherspoon A, Catovsky D. Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment. Leuk Res 2005; 29: 225-228.
6. Lundin J, Porwit-MacDonald A, Rossman ED, Karlsson C, Edman P, Rezvany MR et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphatic leukemia. Leukemia 2004; 18: 484-490.
7. Laurenti L, Piccioni P, Tarnani M, Chiusolo P, Piccirillo N, Rumi C et al. Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphatic leukemia. Leukemia 2005; 19: 153-154.
8. Österborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567-1574.